New study aims to Fine-Tune treatment timing for advanced stomach and esophageal cancers
NCT ID NCT07000253
First seen May 08, 2026 · Last updated Jun 17, 2026 · Updated 7 times
Summary
This study looks at people with esophageal or stomach cancer that has spread to only a few spots (oligometastases). All participants get 4 months of standard therapy, then are randomly assigned to either 4 more months of drugs before local treatment (surgery or radiation) or immediate local treatment followed by more drugs. The goal is to see which timing leads to better disease control and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Amsterdam University Medical Center
RECRUITINGAmsterdam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
UMC Utrecht
NOT_YET_RECRUITINGUtrecht, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.